Overall, these results suggest that the DT2216 + AZ8055 combination may be a promising therapeutic strategy, particularly against BCL-XL/MCL-1 co-dependent SCLC, and therefore this combination could potentially be tested in clinical trials in the future. The gene discussed is MCL1; the disease is small cell lung carcinoma.